Holen Sie sich die Stockscreener-App
6.71
0.59%
-0.04
Handel nachbörslich:
6.66
-0.05
-0.75%
Schlusskurs vom Vortag:
$6.75
Offen:
$6.76
24-Stunden-Volumen:
6.31M
Relative Volume:
1.26
Marktkapitalisierung:
$1.74B
Einnahmen:
$6.28B
Nettoeinkommen (Verlust:
$700.00M
KGV:
2.4924
EPS:
2.6922
Netto-Cashflow:
$537.00M
1W Leistung:
-4.96%
1M Leistung:
-39.06%
6M Leistung:
-30.03%
1J Leistung:
-62.87%
1-Tages-Spanne:
$6.51
$6.855
1-Wochen-Bereich:
$6.18
$7.05
52-Wochen-Spanne:
$6.18
$18.02
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Vergleichen Sie OGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.71 | 1.75B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
Aviance Capital Partners LLC Takes $599,000 Position in Organon & Co. $OGN - MarketBeat
Institutional Investors May Adopt Severe Steps After Organon & Co.'s (NYSE:OGN) Latest 26% Drop Adds to a Year Losses - 富途牛牛
Organon & Co. $OGN Holdings Cut by Fisher Funds Management LTD - MarketBeat
Organon & Co. Stock Plummets to New 52-Week Low of $6.18 - Markets Mojo
Co. (7XP) stock survive global slowdownQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - MSN
KLCM Advisors Inc. Decreases Stake in Organon & Co. $OGN - MarketBeat
Crisis at Organon: Leadership Ousted Amid Sales Scandal - AD HOC NEWS
Tangible book value per share of Organon & Co. – BMV:OGN - TradingView
Organon & Co. (OGN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
OGN 8-K/A discloses interim Executive Chair compensation terms - Stock Titan
The Vanguard Group files 13G/A for Organon with 13.82% stake - Stock Titan
Organon & Co. Common Stock (NY: OGN - FinancialContent
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
Organon & Co. $OGN Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Organon & Co. (OGN) Stock forecasts - Yahoo! Finance UK
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - Yahoo Finance
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - MarketScreener
Organon & Co. (NYSE:OGN) Downgraded by Piper Sandler to Underweight - MarketBeat
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - MSN
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO exits after internal probe over ‘channel stuffing’ to boost sales - Endpoints News
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):